129 related articles for article (PubMed ID: 38232722)
1. Variations in patterns of prescribing durvalumab in stage III lung cancer: a survey of Australian Medical Oncologists.
Nindra U; Bray V; Karikios D; Shafiei M; Subramaniam S; Ding P; Kao S; Pal A
Oncology; 2024 Jan; ():. PubMed ID: 38232722
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
3. Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey.
Käsmann L; Eze C; Taugner J; Roengvoraphoj O; Belka C; Manapov F
Transl Lung Cancer Res; 2020 Apr; 9(2):288-293. PubMed ID: 32420068
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
7. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C; Filippi AR; Sangalli C; Piperno G; Russano M; Greco C; Scotti V; Proto C; Bennati C; Di Pietro Paolo M; Platania A; Olmetto E; Agustoni F; Teodorani N; Agbaje V; Russo A
Crit Rev Oncol Hematol; 2023 Oct; 190():104108. PubMed ID: 37633350
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
Schmid S; Garcia M; Cheng S; Zhan L; Chotai S; Balaratnam K; Khan K; Patel D; Catherine Brown M; Sachdeva R; Xu W; Shepherd FA; Sacher A; Leighl NB; Bradbury P; Moriarty P; Sara Kuruvilla M; Liu G
Lung Cancer; 2022 Apr; 166():58-62. PubMed ID: 35183992
[TBL] [Abstract][Full Text] [Related]
9. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
Hellyer JA; Aredo JV; Das M; Ramchandran K; Padda SK; Neal JW; Wakelee HA
J Thorac Oncol; 2021 May; 16(5):868-872. PubMed ID: 33539970
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Lobefaro R; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar-Nana F; Ponce S; Dal Maso A; Spotti M; Mielgo-Rubio X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier J; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Planchard D; Mezquita L
Eur J Cancer; 2022 May; 167():142-148. PubMed ID: 35307254
[TBL] [Abstract][Full Text] [Related]
11. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Jazieh K; Gad M; Saad A; Wei W; Pennell NA
Transl Lung Cancer Res; 2021 Jul; 10(7):3071-3078. PubMed ID: 34430348
[TBL] [Abstract][Full Text] [Related]
12. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
13. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
14. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
Hussain S; Klugarova J; Klugar M
Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
[TBL] [Abstract][Full Text] [Related]
16. Guideline Concordance With Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience.
Mir NA; Hull O; Bothwell S; Das D
Fed Pract; 2021 Feb; 38(2):74-78. PubMed ID: 33716483
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
18. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
[TBL] [Abstract][Full Text] [Related]
20. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
